What's new? Log in Free sign up

Solid Biosciences (SLDB)

Company Profile

Company profile

Ticker

SLDB

Exchange

Website

www.solidbio.com

CEO

Mr. Alexander G. Cumbo

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • Gilead Sciences • Biogen • Qiagen • Sterling Check • Bio-Techne • Moderna • Acorda Therapeutics • Saratoga Investment ...

Former names

Solid Biosciences, LLC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

AavantiBio, Inc. • Solid Biosciences Securities Corporation ...

SLDB stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$14.80

Low target

$12.00

High target

$16.00

Truist Securities

Market Outperform

Chardan Capital

Latest filings (excl ownership)

View all

Quarterly report

6 Nov 24

Quarterly report

13 Aug 24

Departure of Directors or Certain Officers

Registration of securities for employees

Notice of effectiveness

Shelf registration (amended)

15 May 24

Quarterly report

15 May 24

Annual report to shareholders

Additional proxy soliciting materials

Definitive proxy

26 Apr 24

Transcripts

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Notice of proposed sale of securities (amended)

Jessie Hanrahan

Notice of proposed sale of securities

Alexander Cumbo

Financial summary

Financial statements Chart SLDB financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	66.33 mm	66.33 mm	66.33 mm	66.33 mm	66.33 mm	66.33 mm
Cash burn (monthly)	10.48 mm	(no burn)	11.73 mm	9.34 mm	7.90 mm	7.60 mm
Cash used (since last report)	44.75 mm	n/a	50.08 mm	39.89 mm	33.75 mm	32.45 mm
Cash remaining	21.57 mm	n/a	16.24 mm	26.43 mm	32.58 mm	33.87 mm
Runway (months of cash)	2.1	n/a	1.4	2.8	4.1	4.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

SLDB institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	99	83	+19.3%
Opened positions	32	34	-5.9%
Closed positions	16	6	+166.7%
Increased positions	28	21	+33.3%
Reduced positions	21	15	+40.0%

13F shares	Current	Prev Q	Change
Total value	248.72 bn	212.31 bn	+17.2%
Total shares	52.85 mm	52.70 mm	+0.3%
Total puts	38.30 k	23.10 k	+65.8%
Total calls	524.20 k	4.30 k	+12090.7%
Total put/call ratio	0.1	5.4	-98.6%

Largest owners	Shares	Value	Change
RARE Ultragenyx Pharmaceutical	7.83 mm	$26.84 mm	0.0%
Perceptive Advisors	6.91 mm	$48.14 bn	0.0%
Ra Capital Management	4.33 mm	$30.18 bn	0.0%
Bain Capital Life Sciences Investors	4.03 mm	$28.12 bn	0.0%
Vestal Point Capital	2.80 mm	$19.52 bn	+5.1%
Siren, L.L.C.	2.75 mm	$19.16 bn	NEW
Artal International S.C.A.	2.72 mm	$20.93 mm	0.0%
Invus Global Management	2.41 mm	$13.80 mm	NEW
BCLS SB Investco	2.30 mm	$18.55 mm	0.0%
Adage Capital Partners GP, L.L.C.	1.75 mm	$12.23 bn	-10.2%

Largest transactions	Shares	Bought/sold	Change
Siren, L.L.C.	2.75 mm	+2.75 mm	NEW
Artal	0.00	-2.50 mm	EXIT
Invus Global Management	2.41 mm	+2.41 mm	NEW
Flynn James E	0.00	-2.26 mm	EXIT
Adage Capital Management	1.75 mm	+1.75 mm	NEW
Deerfield Management	0.00	-1.74 mm	EXIT
BlackRock	1.60 mm	+1.60 mm	NEW
BLK BlackRock	0.00	-1.48 mm	EXIT
Citadel Advisors	920.46 k	+808.04 k	+718.8%
JHG Janus Henderson	0.00	-752.99 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SLDB insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
28 Jan 25	Ganot Ilan	Common Stock	Sell	Dispose S	Yes	No	3.1096	144	447.78	11,689
27 Jan 25	Ganot Ilan	Common Stock	Option exercise	Acquire M	No	No	0	3,883	0.00	98,690
27 Jan 25	Ganot Ilan	Common Stock	Option exercise	Acquire M	Yes	No	0	388	0.00	11,833
27 Jan 25	Ganot Ilan	RSU Common Stock	Option exercise	Dispose M	No	No	0	3,883	0.00	3,884
27 Jan 25	Ganot Ilan	RSU Common Stock	Option exercise	Dispose M	Yes	No	0	388	0.00	389
10 Jan 25	Kevin Tan	Common Stock	Sell	Dispose S	No	No	3.8913	4,073	15.85 k	24,789
9 Jan 25	Kevin Tan	Common Stock	Option exercise	Acquire M	No	No	0	11,250	0.00	28,862
9 Jan 25	Kevin Tan	RSU Common Stock	Option exercise	Dispose M	No	No	0	11,250	0.00	22,500
6 Jan 25	Ganot Ilan	Common Stock	Sell	Dispose S	Yes	No	4.31	1,056	4.55 k	11,445
6 Jan 25	Smith Ian F	RSU Common Stock	Grant	Acquire A	No	No	0	18,293	0.00	18,293

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Solid Biosciences Announces Clinical Pipeline Updates: SGT-003 Tolerated In Duchenne Trial; SGT-212 FA Study For 2H 2025; SGT-501 IND Submission By H1 2025; $148.9M Cash Funding Through 2026

- Duchenne: Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 -- FA: First-in-human clinical study

HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target

HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $16 price target.

HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target

HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $16 price target.

12 Health Care Stocks Moving In Friday's Pre-Market Session

Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development (CORRECTED)

Press releases

From Benzinga Pro

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

- Only dual route gene transfer therapy in development to treat Friedreich's ataxia with FDA IND clearance and Fast Track designation - CHARLESTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc.

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

- Duchenne: Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 - - FA: First-in-human clinical

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

Solid Biosciences Added to the Nasdaq Biotechnology Index

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.